AstraZeneca Results Presentation Deck
BioPharmaceuticals: Respiratory and Immunology
Total Revenue $4.5bn; growth +12%
●
$m
400
300
200
100
0
Q3
Fasenra
32% growth to $901m
Q4 Q1 Q2 Q3 Q4
2019
US Europe EROW EM
2020
Q1
Q2
• US performance driven by NBRx
leadership and volume growth
2021
Q3
Leading biologic in eosinophilic asthma¹
Global performance driven by new
patient share
Fasenra Per 30 mg/ml
Breztri
COPD launch uptake; sales of $130m
Top 8 markets triple FDCs
brand share (DOT)²
Breztri
4%
12%
Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21
Rapidly increasing market share
globally
Demand sales volume increase
in China following NRDL inclusion
ホリエアロスフィ
(6)
レーストリ
56x
DAN
$m
1,000
800
600
400
200
0
Q3
Symbicort
Resilient performance
Q4 Q1
2019
US Europe EROW EM
Q2 Q3 Q4 Q1
2020
• Anti inflammatory reliever now
approved in 42 countries
Symbicort
#1 ICS/LABA
23 1. Based on IQVIA MIDAS consolidated total patient top 7 market share (Markets: US, JP, DE, FR, ES, IT, UK) in Q3 2021. 2. IQVIA MIDAS monthly days of therapy month end Aug-21. NBRX = new to brand prescriptions; COPD = chronic
obstructive pulmonary disorder; FDCs = fixed dose combinations; ICS = inhaled corticosteroid; LABA = long acting beta agonist.
medicine
globally
Q2 Q3
• Resilient performance especially in US,
growth in China
2021
BView entire presentation